BOSTON SCIENTIFIC CORP (BSX)

Current Report Filed: 2026-05-05

Key Insights

Boston Scientific successfully eliminated supermajority voting provisions in its charter, reducing barriers to future takeover attempts and enhancing shareholder voting power with 98.6% approval on the amendment.
The company added officer exculpation provisions under Delaware law, which provides legal protection for officers in certain circumstances but received notably lower shareholder support (87.5% approval) compared to other governance items.
All 10 board directors were re-elected with strong support, though David Habiger and Cathy Smith received lower vote percentages (85.9% and 92.6% respectively) compared to other nominees, potentially signaling selective investor concerns.
Stockholders decisively rejected both proposals regarding special meeting rights (shareholders owning 25% stock), with the stockholder proposal receiving only 42.8% support, indicating investor preference for maintaining existing governance controls.
The company expanded its Employee Stock Purchase Plan with overwhelming approval (99.8%), suggesting management confidence in employee engagement and stock-based compensation strategy.

Quarterly Report Filed: 2026-05-01

Key Insights

Boston Scientific completed multiple strategic acquisitions in Q1 2026, including Penumbra Inc. (January 15), Nalu Medical (January 27), and Scivita Medical, indicating aggressive portfolio expansion and M&A activity to strengthen competitive positioning.
The filing demonstrates active hedging strategies across foreign exchange contracts and net investment hedges, suggesting management is managing currency exposure and international operational risks as the company operates globally.
The company maintains structured debt obligations including Senior Notes due 2027 and December 2027 Notes, requiring careful cash flow management and refinancing planning in the near-term maturity window.
Significant intangible assets related to acquisitions, including technology-based intangibles, patents, and in-process R&D, indicate substantial goodwill and integration risk that could impact future earnings if synergy targets are not achieved.

Current Report Filed: 2026-04-22

Key Insights

Boston Scientific announced Q1 2026 financial results on April 22, 2026, providing investors with the first quarterly performance update of the year through the press release filed as Exhibit 99.1.
The filing confirms the company maintains dual securities listings on NYSE (common stock under ticker BSX and senior notes due 2027 under ticker BSX27), indicating active debt management alongside equity operations.
As a non-emerging growth company, Boston Scientific is subject to full SEC compliance requirements and SOX auditing standards, suggesting it is an established large-cap medical device manufacturer with significant market presence.

Current Report Filed: 2026-03-30

Key Insights

Boston Scientific announced positive results from two key clinical trials, HI-PEITHO and CHAMPION-AF, which could indicate potential product pipeline advancements and growth opportunities.
The company filed this 8-K to disclose the clinical trial results, suggesting these are material events that could impact the stock price.
Investors should monitor the progress of these trials and potential regulatory and commercial milestones that could arise from these developments.

Insider Trading Filed: 2026-03-03

Key Insights

Insider Emily Woodworth, SVP and Global Controller, exercised 838 restricted stock units and sold 372 shares of Boston Scientific common stock on March 1, 2026.
The transaction resulted in Woodworth directly owning 2,859 shares of Boston Scientific, down from 3,231 shares prior to the transaction.
Insiders' transactions can provide signals about a company's future prospects, and should be monitored by investors.

Insider Trading Filed: 2026-02-27

Key Insights

The reporting person, Arthur C. Butcher, who is an EVP & Grp Pres at Boston Scientific Corp, acquired 6,851 shares of common stock through the company's 401(k) Retirement Savings Plan, indicating their confidence in the company's performance.
The reporting person still holds a significant direct ownership of 55,792 shares, suggesting they remain invested in the long-term success of Boston Scientific Corp.
The acquisition of shares through the 401(k) plan indicates the reporting person's commitment to the company and their belief in its growth potential.

Current Report Filed: 2026-02-26

Key Insights

Boston Scientific entered into a $3 billion revolving credit agreement that matures in 2031, providing the company with significant financial flexibility.
The agreement includes an option to extend the maturity by one year, subject to lender approval, indicating the company's ability to negotiate favorable terms.
The agreement allows Boston Scientific to exclude certain cash litigation payments from its financial covenants, potentially mitigating the impact of legal disputes on its leverage ratio.

Current Report Filed: 2026-02-23

Key Insights

Boston Scientific announced the appointment of two new directors, Catherine R. Smith and Christophe P. Weber, to its Board, effective February 18, 2026.
The Board also approved an increase of $4.0 billion to the company's existing stock repurchase program, bringing the total authorization to $5.0 billion.
The new directors will receive standard non-employee director compensation, including a cash retainer and equity award, prorated for the period until the 2026 annual meeting.

Annual Report Filed: 2026-02-17

Key Insights

Boston Scientific reported revenue growth of 7% in 2025, driven by strong performance in its medical device segments.
Gross margins improved by 2 percentage points year-over-year, indicating operational efficiency and cost control.
The company provided positive guidance for 2026, projecting 5-8% revenue growth and margin expansion, which could signal continued momentum.

Current Report Filed: 2026-02-05

Key Insights

Boston Scientific announced that Yoshiaki Fujimori, a member of the Board of Directors since 2016, will not stand for re-election at the 2026 Annual Meeting.
The company stated that Fujimori's decision is not the result of any disagreement with the company, and the Board will evaluate whether to add new directors after his departure.
This change in Board composition could signal a shift in the company's strategic priorities or leadership, which investors should monitor for potential impacts.

Current Report Filed: 2026-02-04

Key Insights

Boston Scientific Corporation reported financial results for the fourth quarter and full year 2025, indicating the company's performance was in line with market expectations.
The company's senior notes due 2027 are publicly traded, providing investors with an additional fixed-income investment option from the medical device manufacturer.
The 8-K filing does not indicate any major leadership changes or material agreements that would significantly impact the company's operations or future outlook.

Insider Trading Filed: 2026-02-03

Key Insights

Insider Michael F. Mahoney, the Chairman, President and CEO of Boston Scientific, has reported multiple transactions, including exercising stock options and selling shares.
The transactions were made pursuant to a pre-established Rule 10b5-1 trading plan, suggesting planned and routine portfolio management rather than a reaction to specific events.
The reported transactions do not indicate any major changes or shifts in Mahoney's ownership or leadership position, maintaining his role as a key insider and significant shareholder.

Current Report Filed: 2026-01-15

Key Insights

Boston Scientific is acquiring Penumbra, a medical device company, in a major transaction that is expected to provide strategic and financial benefits.
The acquisition expands Boston Scientific's product portfolio and market reach, aligning with its growth strategy.
Investors should monitor the integration process and the financial and operational impact of the acquisition on Boston Scientific's future performance.

Current Report Filed: 2026-01-15

Key Insights

Boston Scientific Corporation has entered into an agreement to acquire Penumbra, Inc., a medical device company, for a combination of cash and stock consideration.
The acquisition will expand Boston Scientific's portfolio of medical devices and provide access to Penumbra's innovative products and technologies.
The transaction is subject to customary closing conditions, including regulatory approvals and Penumbra shareholder approval.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information